SG11202009971QA - Quinoline derivatives as inhibitors of axl/mer rtk and csf1r - Google Patents

Quinoline derivatives as inhibitors of axl/mer rtk and csf1r

Info

Publication number
SG11202009971QA
SG11202009971QA SG11202009971QA SG11202009971QA SG11202009971QA SG 11202009971Q A SG11202009971Q A SG 11202009971QA SG 11202009971Q A SG11202009971Q A SG 11202009971QA SG 11202009971Q A SG11202009971Q A SG 11202009971QA SG 11202009971Q A SG11202009971Q A SG 11202009971QA
Authority
SG
Singapore
Prior art keywords
cancer
mmol
mixture
cycloalkyl
lcms
Prior art date
Application number
SG11202009971QA
Other languages
English (en)
Inventor
Kiyean Nam
Jaeseung Kim
Dongsik Park
Yeejin Jeon
Yeong-In Yang
Hwan Kyu Kang
Original Assignee
Qurient Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qurient Co Ltd filed Critical Qurient Co Ltd
Publication of SG11202009971QA publication Critical patent/SG11202009971QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
SG11202009971QA 2018-05-30 2019-05-31 Quinoline derivatives as inhibitors of axl/mer rtk and csf1r SG11202009971QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862677902P 2018-05-30 2018-05-30
PCT/EP2019/064214 WO2019229251A1 (en) 2018-05-30 2019-05-31 Quinoline derivatives as inhibitors of axl/mer rtk and csf1r

Publications (1)

Publication Number Publication Date
SG11202009971QA true SG11202009971QA (en) 2020-11-27

Family

ID=66770463

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009971QA SG11202009971QA (en) 2018-05-30 2019-05-31 Quinoline derivatives as inhibitors of axl/mer rtk and csf1r

Country Status (13)

Country Link
US (1) US12162858B2 (cg-RX-API-DMAC7.html)
EP (1) EP3774776A1 (cg-RX-API-DMAC7.html)
JP (2) JP7390313B2 (cg-RX-API-DMAC7.html)
KR (1) KR102901476B1 (cg-RX-API-DMAC7.html)
CN (1) CN112313216B (cg-RX-API-DMAC7.html)
AU (1) AU2019276359B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020021370A2 (cg-RX-API-DMAC7.html)
CA (1) CA3097694A1 (cg-RX-API-DMAC7.html)
IL (1) IL278960B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020011636A (cg-RX-API-DMAC7.html)
PH (1) PH12020551806A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202009971QA (cg-RX-API-DMAC7.html)
WO (1) WO2019229251A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
EP4499627A1 (en) * 2022-03-30 2025-02-05 Qurient Co., Ltd. New forms of n-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-1-propyl-4-(2,2,2-trifluoroethoxy)-1h-pyrazole-3-carboxamide hydrochloride
KR102921178B1 (ko) * 2023-11-16 2026-02-02 (주)신테카바이오 헤테로아릴 유도체 화합물 및 이의 용도
CN117637185B (zh) * 2024-01-25 2024-04-23 首都医科大学宣武医院 一种基于影像的颅咽管瘤治疗辅助决策方法、系统及设备
CN118593494B (zh) * 2024-08-08 2024-11-01 四川大学华西医院 Nampt抑制剂在制备预防和/或治疗色素沉着绒毛结节性滑膜炎的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
EP2311809A1 (en) 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
MX352844B (es) 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
WO2016104617A1 (ja) 2014-12-25 2016-06-30 小野薬品工業株式会社 キノリン誘導体
KR102499359B1 (ko) * 2015-04-14 2023-02-10 주식회사 큐리언트 Tam rtk 억제제로서 퀴놀린 유도체들
JP2021525755A (ja) * 2018-06-01 2021-09-27 ライジェル ファーマシューティカルズ, インコーポレイテッド チロシンキナーゼ阻害剤として有用なキノリン誘導体

Also Published As

Publication number Publication date
KR102901476B1 (ko) 2025-12-18
WO2019229251A1 (en) 2019-12-05
IL278960B2 (en) 2024-08-01
CN112313216A (zh) 2021-02-02
JP7390313B2 (ja) 2023-12-01
JP2023168629A (ja) 2023-11-24
US12162858B2 (en) 2024-12-10
US20210163448A1 (en) 2021-06-03
IL278960B1 (en) 2024-04-01
PH12020551806A1 (en) 2021-05-17
NZ768747A (en) 2025-06-27
AU2019276359B2 (en) 2024-10-03
AU2019276359A1 (en) 2020-10-29
CA3097694A1 (en) 2019-12-05
EP3774776A1 (en) 2021-02-17
KR20210020882A (ko) 2021-02-24
CN112313216B (zh) 2025-03-14
JP2021525270A (ja) 2021-09-24
BR112020021370A2 (pt) 2021-01-19
IL278960A (en) 2021-01-31
MX2020011636A (es) 2020-12-07

Similar Documents

Publication Publication Date Title
IL278960A (en) History of quinoline as inhibitors of AXL/MER RTK and CSF1R
IL267090A (en) Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors and methods of using them
IL261606A (en) Inhibitors of transfected menin-mll and methods of use
IL267455A (en) Phosphodiesterase inhibitors and methods of treating bacteria
IL267869A (en) Non-aqueous preparations of mTOR inhibitors and methods of use
IL268004B (en) History of tyrosine amide as rho-kinase inhibitors
IL267291B (en) Actonucleotidase inhibitors and methods of using them
IL274504A (en) 2ACSS inhibitors and methods of their use
IL279949A (en) Heterocyclic MCT4 inhibitors
EP3405477C0 (en) TRANSGLUTAMINASE INHIBITORS
LT3558321T (lt) Chinolinų dariniai kaip dyrk1a ir (arba) dyrk1b kinazių inhibitoriai
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
EP3183256A4 (en) Substituted macrocycles useful as kinases inhibitors and methods of use thereof
SG11202106897XA (en) Quinoline compounds as inhibitors of tam and met kinases
HUE050975T2 (hu) Adapter-asszociált kináz 1 inhibitorai, azokat tartalmazó kompozíciók és eljárások alkalmazásukra
PL3362450T3 (pl) N1 i n7-podstawione pochodne sybiriliny oraz ich zastosowania jako inhibitory nekroptozy komórkowej
IL281216A (en) Inhibitors of glutaminyl cyclase
IL270703A (en) History of Reziquimod
EP3237619B8 (en) Compositions and methods for inhibiting expression of adamts-5 and adam17
IL266344A (en) Inhibitors of mtor-deptor interactions and methods of use thereof
EP3433243B8 (en) Novel derivatives and their use as selective inhibitors of caspase-2
GB201709136D0 (en) New therapeutic uses of enzyme inhibitors
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
IL266121A (en) A history of metamorphosed quinoxaline as an inhibitor of pfkfb
HK40039181A (en) Quinoline derivatives as inhibitors of axl/mer rtk and csf1r